WT1 and ovarian cancer: The subgroup analyses revealed that the expression of WT1 predicted the poor DSS (metaHR = 1.82, 95% CI = 1.42–2.73), and DFS/RFS/PFS (metaHR = 2.51, 95% CI = 1.81–3.48) in patients with ovarian cancer.